Form 4: Zentalis Pharmaceuticals' Chief Medical Officer Sells Shares to Cover Tax Obligations

Diana Hausman, Chief Medical Officer of Zentalis Pharmaceuticals, sold 3,356 shares of common stock on May 9, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• On May 9, 2024, Diana Hausman, the Chief Medical Officer of Zentalis Pharmaceuticals, sold 3,356 shares of the company's common stock.
• The sale was executed at a price of $12.62 per share.
• This transaction was conducted automatically by the issuer to cover tax withholding obligations associated with the vesting and settlement of restricted stock units previously granted to Ms. Hausman.
• Following the transaction, Ms. Hausman still beneficially owns 373,876 shares of Zentalis Pharmaceuticals' common stock.

Sentiment

Score: 6

Explanation: The document is a routine SEC filing related to a stock sale for tax purposes. It doesn't indicate any significant positive or negative sentiment regarding the company's performance or outlook.

Industry Context

Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among corporate executives.

Stakeholder Impact

• The sale of shares by a company executive could have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.

Key Dates